相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero et al.
LANCET ONCOLOGY (2016)
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy
Lewis R. Silverman et al.
HEMATOLOGICAL ONCOLOGY (2015)
Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation
Betul Oran et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring
Rajyalakshmi Luthra et al.
HAEMATOLOGICA (2014)
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
John Koreth et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
Stefan Faderl et al.
CANCER (2012)
Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, and Blast- Phase Chronic Myeloid Leukemia
Elias Jabbour et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Detection of High-Frequency and Novel DNMT3A Mutations in Acute Myeloid Leukemia by High-Resolution Melting Curve Analysis
Rajesh R. Singh et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
Acute Myeloid Leukemia With IDH1 or IDH2 Mutation Frequency and Clinicopathologic Features
Keyur P. Patel et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Outcome of Patients With Myelodysplastic Syndrome After Failure of Decitabine Therapy
Elias Jabbour et al.
CANCER (2010)
Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome
Stefan Faderl et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Mechanisms of Disease: Myelodysplastic Syndromes.
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl et al.
BLOOD (2008)
Clofarabine: Past, present, and future
Hagop M. Kantarjian et al.
LEUKEMIA & LYMPHOMA (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study
H Kantarjian et al.
CANCER (2006)
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
S Faderl et al.
BLOOD (2005)
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
H Kantarjian et al.
BLOOD (2003)
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers
HM Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
分享论文
